Search results for " age-related macular degeneration"

showing 10 items of 10 documents

Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease

2020

Abstract Background Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD. Methods To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loc…

0301 basic medicinegenetic structures610 MedizinGenome-wide association studyMacular Degeneration0302 clinical medicineAdvanced diseaseCD46Genetics (clinical)GeneticsInternational AMD genomics consortium (IAMDGC)ddc:6100303 health sciencesGenome-wide association study (GWAS)3. Good health030220 oncology & carcinogenesisAge-related macular degeneration (AMD)Meta-analysisResearch ArticleGenetic Markerslcsh:Internal medicineUK biobank (UKBB)lcsh:QH426-470Locus (genetics)GenomicsComputational biologyBiologyPolymorphism Single NucleotideGenome-wide association study (GWAS) Meta-analysis Age-related macular degeneration (AMD) Early AMD CD46 TYR International AMD genomics consortium (IAMDGC) UK biobank (UKBB) Machine-learning Automated phenotyping03 medical and health sciencesEarly AMDGeneticsmedicineHumansGenetic Predisposition to DiseaseGenome-wide Association Study (gwas) ; Meta-analysis ; Age-related Macular Degeneration (amd) ; Early Amd ; Cd46 ; Tyr ; International Amd Genomics Consortium (iamdgc) ; Uk Biobank (ukbb) ; Machine-learning ; Automated Phenotypinglcsh:RC31-1245Machine-learning030304 developmental biologyTYRCD46Macular degenerationmedicine.diseaseHuman geneticseye diseasesGenetic architectureMeta-analysislcsh:Genetics030104 developmental biologyGenetic LociCase-Control StudiesAutomated phenotypingHTRA1030221 ophthalmology & optometrysense organsGenome-Wide Association Study
researchProduct

Problématiques de la nutrition en ophtalmologie – application à la dégénérescence maculaire liée à l’âge

2014

Nutrition in ophthalmology – clinical application to age-related macular degeneration «Let food be your medicine.» This contribution from Hippocrates is still timely addressed, especially in the field of ophthalmology. Observational epidemiology reports close associations between food habits and the risk or prevention of several ocular pathologies such as cataract or Age-related Macular Degeneration (AMD). Anti-oxidant vitamins, minerals and lipids are the nutrients that have been the most widely studied. Interventional epidemiology and experimental works partially corroborated these findings. Unexpectedly, the benefit of long chain omega 3 polyunsaturated fatty acids in the prevention of l…

2. Zero hungerretinaGeneral Veterinarygenetic structuresPhilosophyage related macular degenerationfood[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionagingnutrition ; alimentation ; rétine ; lipides ; caroténoïdes ; prévention ; vieillissement ; dégénérescence maculaire liée à l’âge.eye diseasescarotenoid3. Good health[SDV.AEN] Life Sciences [q-bio]/Food and Nutritionprevention ; food ; aging ; age-related macular degeneration. ; diet ; carotenoids ; lipids ; retinaprevention[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organslipid[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organssense organs[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansdietHumanities[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice …

2022

Abstract Purpose PERSEUS-IT (NCT02289924) was a prospective, observational, 2-year study evaluating the effectiveness and treatment patterns of intravitreal aflibercept (IVT-AFL) in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice in Italy. Methods Treatment-naïve patients with nAMD receiving IVT-AFL per routine clinical practice were enrolled. The primary endpoint was mean change in visual acuity (VA; decimals) from baseline to month (M) 12 and M24. Outcomes were evaluated for the overall study population and independently for the 2 treatment cohorts: regular (3 initial monthly doses, ≥ 7 injections by M12, and ≥ 4 injections between M12 and M2…

Intravitreal injectionsSettore MED/30 - Malattie Apparato VisivoRecombinant Fusion ProteinsAngiogenesis InhibitorsTreatment outcomesSensory SystemsMacular DegenerationCellular and Molecular NeuroscienceOphthalmologyReceptors Vascular Endothelial Growth FactorTreatment OutcomeRanibizumabObservational studyHumansProspective StudiesAfliberceptNeovascular age-related macular degeneration
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).

2009

Purpose This prospective study examines the changes in short-term intraocular pressure (IOP) in patients with wet age-related macular degeneration (AMD) receiving intravitreal injections of 0.05 mL ranibizumab (Lucentis®) in a supine position. Methods A total of 45 eyes (45 patients, 16 M, 29 F, mean age: 78 y) received intravitreal ranibizumab injections for treatment of wet AMD (0.05 mL = 0.5 mg). The IOP was measured by Schiötz tonometry immediately preoperatively and postoperatively, and also after 3 and 10 minutes in a supine position. No history of glaucoma was present. Results The mean preoperative IOP was 22.4±5.5 mmHg in supine position. Immediately after the injection, IOP increas…

MaleVascular Endothelial Growth Factor AIntraocular pressuremedicine.medical_specialtySupine positiongenetic structuresAngiogenesis InhibitorsAntibodies Monoclonal HumanizedInjections03 medical and health sciencesTonometry Ocular0302 clinical medicineOphthalmologyRanibizumabWet age-related macular degenerationmedicineSupine PositionHumansIn patientProspective StudiesProspective cohort studyIntraocular PressureAgedAged 80 and overbusiness.industryAntibodies MonoclonalGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseeye diseasesVitreous BodyOphthalmology030221 ophthalmology & optometryWet Macular DegenerationFemalesense organsRanibizumabbusiness030217 neurology & neurosurgerymedicine.drugEuropean journal of ophthalmology
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR D…

2007

Abstract PURPOSE: To assess the effectiveness of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV) associated with retinal pigment epithelium detachment (PED) in age-related macular degeneration. METHODS: Thirty eyes of 26 patients with CNV and PED were treated with PDT. The eyes were divided in two groups based on CNV location in relation to PED; group 1 included 13 eyes with CNV within PED, and group 2 included 17 eyes with CNV at the edge of PED. The median follow-up was 16 months. RESULTS: Patients received a mean +/- SD of 2.83 +/- 1.26 treatments (range, 1-6 treatments). In the whole cohort, the mean preoperative visual acuity changed from 20/144 (0.86…

Malemedicine.medical_specialtyPorphyrinsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyMacular DegenerationAge relatedOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyPigment Epithelium of EyeAgedAged 80 and overPhotosensitizing AgentsRetinal pigment epitheliumSettore MED/30 - Malattie Apparato Visivobusiness.industryRetinal DetachmentVerteporfinGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyFemaleRetinal pigment epithelial detachmentsense organsPhotodynamic therapy choroidal neovascularization age-related macular degenerationmedicine.symptombusinessFollow-Up Studiesmedicine.drugRetina
researchProduct

Evidence of neuroplasticity in the human visual cortex following beneficial anti-VEGF treatment in exudative age-related macular degeneration

2012

Purpose Anti-vascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration (AMD). As the vision improves relatively quickly in response to intravitreal injections, we wanted to know whether this improvement is reflected in electrophysiolocal markers of visual cortical processing. Methods Our interventional case series included 6 elderly patients who underwent injection treatment to the affected eye. Their visual acuity, tomographic images of retinal thickness and visual evoked potentials (VEP) were assessed before of the treatment and six weeks after the last injection. Results All patients sho…

Retinamedicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryRetinalGeneral MedicineMacular degenerationAudiologymedicine.diseaseExudative age-related macular degenerationeye diseasesOphthalmologychemistry.chemical_compoundmedicine.anatomical_structureVisual cortexchemistryOphthalmologyNeuroplasticityMedicinesense organsAnti vegf treatmentmedicine.symptombusinessActa Ophthalmologica
researchProduct

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

2022

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 m…

Vascular Endothelial Growth Factor Atype 3 neovascularization.brolucizumabNeovascularization PathologicVisual Acuityneovascular age-related macular degeneration; type 3 neovascularization; retinal angiomatous proliferation; brolucizumab; optical coherence tomography angiography; intravitreal injectionintravitreal injectionretinal angiomatous proliferationEndothelial Growth Factorsneovascular age-related macular degenerationGeneral MedicineAntibodies Monoclonal Humanizedoptical coherence tomography angiographyIntravitreal InjectionsHumansFluorescein AngiographyTomography Optical CoherenceRetrospective StudiesMedicina
researchProduct

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

2013

Pasi Vottonen,1 Kai Kaarniranta,1,2 Ari Pääkkönen,3 Ina M Tarkka41Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; 2Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 3Department of Clinical Neurophysiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Health Sciences, University of Jyväskylä, Jyväskylä, FinlandPurpose: Antivascular endothelial growth factor (VEGF) agents have been shown to improve visual acuity and prevent vision loss in exudative age-related macular degeneration. As the vision im…

medicine.medical_specialtyVisual acuityexudative age-related macular degenerationvisual acuitygenetic structuresvisual evoked potentialsVEGF receptorsta3112Cortical processingVisual processingText miningOphthalmologymedicinescalp-recorded EEGage-related eye diseasesOriginal Researchbiologybusiness.industryta3141Clinical OphthalmologyMacular degenerationmedicine.diseaseeye diseasesOphthalmologybiology.proteinElectrophysiological markerssense organsAnti vegf treatmentmedicine.symptombusinessClinical Ophthalmology
researchProduct